Antibody Engineering & Antibody Therapeutics
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to Antibody Engineering & Antibody Therapeutics — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds
About this event
Antibody Engineering & Therapeutics 2026 (AET US)
Antibody Engineering & Therapeutics 2026 is the flagship antibody and protein engineering conference bringing together leading antibody scientists and research professionals to advance the next generation of antibody therapeutics. Held in a focused, high-impact format, the conference covers the end-to-end innovation path—from protein engineering and bispecific/multispecific formats to therapeutic translation and commercialization-ready strategies.
Event dates & location
- Dates: December 13 - 16, 2026
- Venue: Marriott Marquis San Diego
- City: San Diego
- Country:
What the conference is about
Antibody Engineering & Therapeutics 2026 positions itself as a targeted summit for protein engineering excellence and the practical acceleration of antibody therapeutics. The program is built around core themes including: antibodies, proteins, bispecifics, multispecifics, ADCs, immunology, and AI-driven discovery and computational breakthroughs. Across four intensive days, attendees engage with scientific content and collaborative formats designed to support R&D teams moving discoveries from concept toward clinic and beyond.
Attendee and industry relevance
The conference is described as a strategic investment for R&D groups that want to apply cutting-edge innovation to fast-track antibody programs. It also emphasizes cross-ecosystem connection points through:
- 900+ international attendees connecting and collaborating
- 165 global expert speakers delivering insights across antibody engineering and therapeutic development
- 97 sponsors showcasing solutions
- 158 posters presenting the latest discoveries from scientists worldwide
- 10 hours of dedicated networking including receptions, social hours, and poster viewing
Program highlights (key technical tracks)
Antibody Engineering & Therapeutics 2026 focuses on current and next-wave scientific priorities in antibody therapeutics and engineering. Key program areas include:
- Novel bispecific and multispecific antibodies designed to address therapeutic limitations and improve functional performance.
- Case studies on bispecific ADCs and conditional activation platforms emphasizing real-world engineering pathways and translational logic.
- Engineering strategies for glycan targeting, avidity, and stability to strengthen efficacy and durability.
- Antibody therapeutics in emerging disease areas (non-oncology) including fibrosis, cardiovascular disease, and CNS delivery.
- Innovative biologics targeting innate and adaptive immune pathways for translational immunology approaches.
- Engineering innovative formats for cell engagers, including AI-driven design and next-gen T-cell engager platforms focused on potency, selectivity, and safety.
- Antibody and protein therapeutics in inflammation, autoimmunity, and allergy, featuring advances such as cytokine blockers and trispecific antibodies.
- Emerging in vitro approaches to antibody discovery covering display technologies and high-throughput screening platforms.
- Computational and AI-driven antibody engineering for speed, precision, and de novo design strategies.
- Engineering innovative formats and scaffolds including nanobody and knottin engineering, GPCR-targeting formats, and scaffold innovations to address immunogenicity.
- Advanced in vivo antibody discovery approaches leveraging animal models to inform therapeutic development.
Networking and collaboration
The conference is structured to encourage scientific exchange and relationship-building. With 10 hours of dedicated networking across receptions, social hours, and poster viewing, participants can connect with peers, research leaders, and solution providers while exploring new ideas and potential collaboration opportunities.
Who should attend
Antibody Engineering & Therapeutics 2026 is well suited for professionals involved in antibody discovery, antibody engineering, translational development, and therapeutic platform design—especially teams working on bispecific/multispecific formats, ADC-related strategies, immune pathway targeting, computational or AI-driven discovery, and next-generation therapeutic modalities.
Event theme
The conference theme centers on Protein Engineering Excellence and accelerating innovation in antibody therapeutics. It positions the summit as the place where antibody science meets practical paths to commercial and clinical success, supported by expert keynotes, technical sessions, poster presentations, and sponsor-supported demonstrations.
Data sheet
Antibody Engineering & Antibody Therapeutics – Event Attendee & Buyer Profile Analysis
Event date: December 13–16, 2026
Location: Marriott Marquis, San Diego, CA, United States
Event status: Upcoming
Research date: June 30, 2026
Event Overview
| Event Name | Antibody Engineering & Antibody Therapeutics 2026 (AET US) |
| Event Date | December 13–16, 2026 |
| Event Status | Upcoming |
| Venue | Marriott Marquis San Diego |
| City | San Diego |
| State / Region | California |
| Country | United States |
| Organizer | Informa Connect (Informa PLC) |
| Official Event Website | informaconnect.com/antibody-engineering-therapeutics/ |
| Event Type | Conference / Scientific Summit / Industry Networking Event |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; Business Services |
| Audience Reach | Global scientific and commercial audience |
| Estimated Attendance / Expected Footfall | 900+ international attendees (official website claim); attendance figure not publicly confirmed by the organizer as a final audited number |
| Attendance Data Reliability | High for promotional estimate; Medium for independently verified count |
| Main Purpose of Event | To showcase antibody and protein engineering breakthroughs, connect R&D and therapeutic-development stakeholders, and accelerate discovery-to-clinic pathways |
About the Event
Antibody Engineering & Antibody Therapeutics 2026 is the flagship antibody and protein engineering conference from Informa Connect, focused on the scientific and commercial development of next-generation biologics. The official event materials position the conference around breakthrough topics such as bispecific and multispecific antibodies, ADCs, AI-driven discovery, computational engineering, immune-pathway targeting, and emerging non-oncology therapeutics.
The event matters because it draws a highly specialized audience of scientists, translational leaders, biotech executives, and solution providers working across antibody discovery, optimization, manufacturing, and therapeutic development. For B2B outreach, it is especially relevant for vendors selling lab technologies, CRO/CDMO services, informatics, instrumentation, reagents, and platform solutions supporting biologics R&D, while also serving as a networking venue for partnerships, licensing, and scientific collaboration.
1. Who Attends: Buyers / Attendees
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| R&D / Discovery Scientists | Biotech firms, pharma R&D centers, research institutes | Technical evaluator; identifies platforms, reagents, and workflow tools | Very high for assay, screening, engineering, and analytics suppliers |
| Translational Medicine Leaders | Biopharma, biotech, academic medical centers | Influences candidate selection and development strategy | High for development, biomarker, and translational platform vendors |
| Protein Engineering Teams | Therapeutics companies, platform biotech, CROs | Selects engineering tools, software, and service providers | Very high for computational and wet-lab workflow solutions |
| Therapeutic Area Leaders | Immunology, oncology, inflammation, CNS, fibrosis teams | Sets scientific priorities; validates unmet-need fit | High for platform and modality solution providers |
| Biologics / Antibody Platform Heads | Large pharma, biotech platform companies | Decision-maker for platform selection, partnerships, and outsourcing | Very high for strategic vendors and service providers |
| Business Development / Alliance Management | Biopharma, biotech, research tools companies | Assesses partnering, licensing, and co-development opportunities | High for platforms, IP, and deal-making services |
| Procurement / Strategic Sourcing | Pharma, biotech, CRO/CDMO, universities | Purchasing authority for services, tools, and enterprise contracts | Medium to high; strongest for recurring supply/service deals |
| CRO / CDMO Leadership | Biologics service providers, contract labs, manufacturing partners | Buys instrumentation, software, reagents, and outsourcing capacity | High for enabling technologies and supplier partnerships |
| Data / AI / Computational Biology Leaders | Pharma, biotech, informatics vendors | Specifies analytics, model-building, and design platforms | Very high for AI, software, cloud, and data vendors |
| Investors / Corporate Development | Life sciences VC, pharma BD, strategic investors | Evaluates platform value, partnerships, and acquisition potential | Medium; useful for innovation scouting and deal flow |
2. Event Location and Attendee Geographic Origin
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Host City | San Diego-based biotech, pharma, and research organizations | Medium | Strong life sciences ecosystem supports local participation |
| Host State / Region | California life sciences corridor, including San Diego, Los Angeles, Bay Area, and Orange County | High | High concentration of biotech, medtech, and pharma decision-makers |
| Nearby Business Hubs | West Coast biotech and pharma hubs | High | Includes Seattle, South San Francisco, San Jose, San Diego, and Greater Los Angeles |
| National Reach | U.S. biotech, pharma, CRO/CDMO, academic, and investor community | Very High | The conference is positioned as a flagship U.S. event |
| International Reach | Europe, Asia, Canada, and other global life sciences hubs | High | Official site describes global impact across US, Europe & Asia |
| Key Trade Corridors | U.S. West Coast, transatlantic biotech collaboration lanes | Medium to High | Relevant for licensing, outsourcing, and cross-border research partnerships |
3. Audience Reach
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | Official content states global impact across US, Europe, and Asia, with international attendees and speakers |
4. Sample Buyer Companies and Websites
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| AstraZeneca | Pharma buyer / speaker organization | Keynote speaker organization; major biologics and antibody developer | astrazeneca.com | VP R&D, Translational Medicine Director, Antibody Discovery Head | Confirmed Speaker Organization |
| Ragon Institute of MGH, MIT and Harvard | Research institute / speaker organization | Scientific leadership in antibody and immunology research | ragoninstitute.org | Scientific Director, Principal Investigator, Immunology Program Lead | Confirmed Speaker Organization |
| Technical University of Denmark | Academic research organization / speaker organization | Antibody technologies expertise; strong research buyer influence | dtu.dk | Professor, Group Leader, Lab Director | Confirmed Speaker Organization |
| Genentech | Biopharma buyer | Large antibody and biologics innovator; strong fit for engineering tools and services | gene.com | Director Antibody Engineering, Procurement Manager, BD Lead | Strong Market Fit, Attendance Not Confirmed |
| Amgen | Biotech buyer | Major biologics and therapeutic development organization | amgen.com | VP Biology, Protein Engineering Director, Sourcing Manager | Strong Market Fit, Attendance Not Confirmed |
| Regeneron | Biopharma buyer | Known for antibody-based medicines and biologics R&D | regeneron.com | Director Antibody Discovery, Program Manager, Category Manager | Strong Market Fit, Attendance Not Confirmed |
| AbbVie | Pharma buyer | Large immunology and oncology biologics portfolio | abbvie.com | VP Immunology R&D, Procurement Director, Alliance Manager | Strong Market Fit, Attendance Not Confirmed |
| GSK | Pharma buyer | Active in immunology and biologics development; relevant for platform and service vendors | gsk.com | Head of Biologics, Sourcing Lead, Scientific Director | Strong Market Fit, Attendance Not Confirmed |
| Sanofi | Pharma buyer | Biologics and immunology portfolio creates direct relevance | sanofi.com | Director Translational Medicine, Procurement Lead, External Innovation Head | Strong Market Fit, Attendance Not Confirmed |
| Bristol Myers Squibb | Pharma buyer | Deep interest in biologics, immunology, and oncology therapeutics | bms.com | VP Biology, Sourcing Manager, Alliance Director | Strong Market Fit, Attendance Not Confirmed |
| Eli Lilly and Company | Pharma buyer | Large R&D organization; strong fit for antibody engineering solutions | lilly.com | Director Discovery Biology, Procurement Director, Program Lead | Strong Market Fit, Attendance Not Confirmed |
| Novartis | Pharma buyer | Global biologics and immunology stakeholder | novartis.com | Head of Antibody Discovery, Strategic Sourcing, BD Lead | Strong Market Fit, Attendance Not Confirmed |
| Roche / Genentech | Biopharma buyer | Antibody engineering and translational drug development relevance | roche.com | Director Biologics, Procurement Lead, External Innovation Manager | Strong Market Fit, Attendance Not Confirmed |
| Ares Pharma / emerging biotech category | Biotech buyer | Representative of smaller antibody-focused biotechs attending for partnering and tools | — | CEO, CSO, Head of Discovery, Lab Director | Historical / prior-year evidence |
5. Job Profiles, Industries and Event Type
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Chief Scientific Officer / Chief Technology Officer | Executive | C-Level | Sets platform strategy and investment priorities |
| 2 | VP, R&D / VP, Biology / VP, Translational Medicine | R&D | VP | Controls research budget and pipeline direction |
| 3 | Director, Antibody Discovery / Protein Engineering | Discovery Biology | Director | Core buyer for engineering platforms and services |
| 4 | Principal Scientist / Senior Scientist | Research | Senior IC | Evaluates lab tools and day-to-day workflow fit |
| 5 | Head of Computational Biology / AI Discovery | Data Science / Informatics | Director+ | Relevant for AI-led antibody design and modeling solutions |
| 6 | Procurement Manager / Strategic Sourcing Manager | Procurement | Manager+ | Purchases instruments, services, and software |
| 7 | Business Development Director / Alliance Director | Business Development | Director+ | Evaluates partnerships, licensing, and co-development |
| 8 | Program Manager / Project Manager | Program Management | Manager | Coordinates cross-functional adoption and vendor evaluation |
| 9 | Lab Director / Core Facility Director | Research Operations | Director | Influences procurement of platforms and lab infrastructure |
| 10 | CRO/CDMO Business Unit Leader | Operations / Commercial | Director+ | Buys enabling technologies and service partnerships |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Biotechnology | Core audience for antibody discovery and therapeutic development | Discovery platforms, reagent suppliers, CROs |
| 2 | Pharmaceuticals | Large buyers of antibody technologies, services, and partnerships | Enterprise solution sales and strategic accounts |
| 3 | Research | Scientific research community is central to the conference | Academic and translational research tools |
| 4 | Medical Devices | Relevant for diagnostics, assay platforms, and adjacent biologics tools | Assay, instrumentation, and workflow adjacent sales |
| 5 | Medical Practice | Clinical translation and physician-scientist participation can be relevant | Clinical insight and translational networking |
| 6 | Hospital & Health Care | Clinical development and collaboration opportunities | Clinical trial, translational, and biomarker services |
| 7 | Computer Software | AI, informatics, and computational biology are explicit themes | Bioinformatics and AI-driven design tools |
| 8 | Information Technology & Services | Data platforms, cloud compute, and digital workflows support antibody discovery | Enterprise software and cloud solutions |
| 9 | Management Consulting | Strategy, partnering, and innovation advisory | Advisory services and market intelligence |
| 10 | Business Supplies & Equipment | Lab operations, workflow equipment, and supply-chain buyers attend relevant scientific events | Lab equipment, consumables, and distribution |
| 11 | Environmental Services | Supporting lab and facility sustainability initiatives | Sustainability and waste management offerings |
6. Estimated Attendance
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | 900+ international attendees | Estimated / promotional | Official website promotional copy | Not an independently audited attendance count |
| Exhibitor / sponsor count | 97 sponsors | Confirmed promotional | Official website | Sponsors listed as 97 on event page |
| Buyer / attendee count | Not publicly confirmed | Unknown | Organizer does not provide a buyer-only breakdown | Attendance figure not publicly confirmed by the organizer. |
| Speaker count | 165 global expert speakers | Estimated / promotional | Official website | As listed on event promotion page |
| Poster count | 158 posters | Estimated / promotional | Official website | Useful for scientific networking and lead capture |
| Networking time | 10 hours dedicated networking | Confirmed promotional | Official website | Supports attendee list building and relationship selling |
7. Key Focus Areas and Buyer Engagement
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Antibody discovery | Higher throughput, better hit quality, faster selection | Demo of screening, display, and selection workflows | Library platforms, screening services, reagents |
| Protein engineering | Stability, affinity, developability, manufacturability | Position engineering tools around practical therapeutic outcomes | Design software, mutagenesis tools, analytics |
| Bispecifics / multispecifics | Novel formats and safety / potency improvements | Speak to multi-target therapeutic design and translational risk reduction | Engineering platforms, expression systems, analytics |
| ADCs and cell engagers | Selective payload delivery, efficacy, and safety | Solution selling to oncology and immunology teams | Linkers, conjugation tech, assay services |
| AI / computational discovery | Faster design cycles and better candidate prioritization | Target data-science buyers with model performance and integration messaging | ML software, cloud compute, databases |
| Non-oncology indications | Fibrosis, CNS, autoimmunity, cardiovascular disease | Align offerings to disease-area priorities and unmet medical need | Biology services, translational models, biomarker tools |
| Manufacturing / developability | Scale-up readiness and CMC feasibility | Engage CMC, manufacturing, and CDMO stakeholders | CMC services, analytical testing, process development |
| Partnerships / licensing | External innovation and deal flow | Pitch strategic collaboration and co-development opportunities | Technology transfer, advisory, alliance support |
Lead Quality Assessment
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | Very High | Strong concentration of antibody, biologics, and translational decision-makers |
| Decision-maker availability | High | Likely presence of scientific directors, VPs, and alliance leaders |
| Data collection potential | High | Sponsor and speaker content supports rich targeting, but current attendee list is not publicly confirmed |
| Apollo targeting potential | Very High | Clear industry and title mapping for pharma, biotech, research, and software buyers |
| Geographic targeting potential | High | Useful U.S. West Coast and global targeting, especially life sciences clusters |
| Best outreach approach | Account-based and role-based outreach | Target company accounts, then filter by antibody, biologics, procurement, and data roles |
| Overall lead quality | Very High | Strong scientific density and commercial relevance for life-science suppliers |
| Best use case | B2B attendee list building, sponsor prospecting, solution sales, partnership outreach | Best for suppliers selling to discovery, translational, and biologics teams |
| Limitations / risks | Moderate | No fully public current-year attendee list; some figures are promotional estimates |
Apollo.io Targeting Recommendation
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Biotechnology; Pharmaceuticals; Research; Medical Devices; Hospital & Health Care; Computer Software; Information Technology & Services | Core buyer universe for antibody discovery, development, and digital tools |
| Departments | R&D; Research; Procurement; Business Development; Operations; Data Science; Translational Medicine | Find both technical evaluators and commercial buyers |
| Seniority | Manager, Director, VP, CXO, Owner | Prioritize decision-makers and budget holders |
| Job titles | CSO, CTO, VP R&D, Director Antibody Discovery, Head of Protein Engineering, Translational Medicine Director, Procurement Director, Strategic Sourcing Manager, Alliance Director, Lab Director, Data Science Director | High-intent title set for attendee targeting and outreach sequences |
| Geography | United States; California; West Coast; Europe; United Kingdom; Switzerland; Denmark; Germany; Japan | Matches the event’s global scientific footprint |
| Employee size | 51–200; 201–500; 501–1,000; 1,001–5,000; 5,001+ | Covers biotechs, mid-market suppliers, and large pharma enterprises |
| Keywords | antibody, protein engineering, biologics, bispecific, multispecific, ADC, immunology, translational medicine, AI drug discovery, computational biology | Narrow to event-relevant accounts and contacts |
| Company type | Public company; private company; research institute; academic medical center; CRO/CDMO | Separates commercial buyers from research collaborators |
Suggested Apollo Search Logic: ("antibody" OR "protein engineering" OR biologics OR bispecific OR multispecific OR ADC OR immunology OR translational medicine) AND (Director OR VP OR Head OR Manager OR Scientist OR Procurement OR Sourcing OR Alliance)
Client Fit Review Required
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
Sources & Verification Notes
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| Informa Connect official event page | Official organizer source | Event name, dates, venue, agenda themes, speakers, sponsor counts, attendee estimate | High |
| Informa Connect corporate website | Organizer reference | Organizer identity and division structure | High |
| Preliminary agenda page | Official agenda / program page | Scientific focus areas and program structure | High |
| 2026 speakers page | Official speaker listing | Confirmed 2026 speaker organizations and scientific leadership profiles | High |
| 2026 sponsors page | Official sponsor listing | Sponsor participation and commercial ecosystem around the event | High |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to Antibody Engineering & Antibody Therapeutics — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds